This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder | MicrobiomeTrials
← Back to trials NCT06229210
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-01-25Est. Completion: 2032-04-28
Enrollment target: 300 participantsLocations Southwest Autism Research and Resource Center, Phoenix, Arizona, United States Pillar Clinical Research, LLC, Little Rock, Arkansas, United States Advanced Research Center, Inc, Anaheim, California, United States National Institute Of Clinical Research, Garden Grove, California, United States Excell Research Inc, Oceanside, California, United States Inland Psychiatric Medical Group Inc, Redlands, California, United States University Of California - Davis, Sacramento, California, United States University Of California San Diego, San Diego, California, United States Next Level Clinical Trials, LLC, West Covina, California, United States MCB Clinical Research Centers LLC, Colorado Springs, Colorado, United States Royal Palm Clinical Research, Fort Myers, Florida, United States Sarkis Clinical Trials, Gainesville, Florida, United States United Research Institute, Hialeah, Florida, United States Advanced Research Institute of Miami, Homestead, Florida, United States Green Leaf Clinical Trials, Jacksonville, Florida, United States Other microbiome trials you might be interested in SCHIZOPHRENIA 1 (Disorder)
This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol t…
Shanghai, China Est. completion Dec 30, 2027
Schizoaffective Disorder
Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging…
Elâzığ, Turkey (Türkiye) Completed Jun 2, 2026
Vital Care Research, Miami, Florida, United States
Columbus Clinical Services LLC, Miami, Florida, United States
Care Research Center Inc, Miami, Florida, United States
Blue Medical Research, Miami, Florida, United States
AP Medical Research, Miami, Florida, United States
Envision Trials LLC, Miami, Florida, United States
GTL Medical and Research Group, Miami, Florida, United States
Diverse Clinical Research LLC, Miami, Florida, United States
Links Clinical Trials, Miami, Florida, United States
New Med Research Inc, Miami Gardens, Florida, United States
The Angel Medical Research Corporation, Miami Gardens, Florida, United States
Riveldi Biomedical Research, Miami Lakes, Florida, United States
APG Research LLC, Orlando, Florida, United States
Clinical Research Center of Florida, Pompano Beach, Florida, United States
University of South Florida Rothman Center of Neuropsychiatry, St. Petersburg, Florida, United States
Health Synergy Clinical Research, West Palm Beach, Florida, United States
CenExeli Research LLC, Atlanta, Georgia, United States
Atlanta Center for Medical Research, Atlanta, Georgia, United States
Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States
Salveo Integrative Health Inc, Lawrenceville, Georgia, United States
CenExeli Research LLC 1, Savannah, Georgia, United States
Baber Research Group, Naperville, Illinois, United States
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
Midwest Research Group 1, Saint Charles, Missouri, United States
Alivation Research LLC, Lincoln, Nebraska, United States
Clinical Research of Southern Nevada, LLC, Las Vegas, Nevada, United States
NYU Child Study Center, New York, New York, United States
Richmond Behavioral Associates, Staten Island, New York, United States
Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Charak Center for Health and Wellness, Garfield Heights, Ohio, United States
Cutting Edge Research Group, Oklahoma City, Oklahoma, United States
Sooner Clinical Research, Oklahoma City, Oklahoma, United States
Access Clinical Trials, Nashville, Tennessee, United States
Texas Research Group, Coppell, Texas, United States
PsyMed Solutions, Fort Worth, Texas, United States
Kaleidoscope Clinical Research, Houston, Texas, United States
Red Oak Psychiatry Associates, Houston, Texas, United States
AIM Trials, Plano, Texas, United States
Perceptive Pharma Research, Richmond, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Northwest Clinical Research Center, Bellevue, Washington, United States
Core Clinical Research, Everett, Washington, United States
HOMO - ESE Hospital Mental de Antioquia, Bello, Colombia
Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia
Institute of Mental Health Serbia, Belgrade, Serbia
University Clinical Center NIS, Niš, Serbia
Clinical Center of Vojvodina, Novi Sad, Serbia Treatment-resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, s…
Los Angeles, United States Est. completion Mar 31, 2027